

Supplementary Table 2. Country-Wise Distribution of Patients in the Asian Countries Subgroup of GEMINI 2 Patients: Maintenance Phase

Country	ITT				Non-ITT			All
	Placebo	Vedolizumab q8w	Vedolizumab q4w	All	Placebo	Vedolizumab q4w	All	
Hong Kong	0	0	0	0	2	0	2	2
India	3	4	4	11	10	13	23	34
South Korea	2	3	5	10	3	13	16	26
Malaysia	2	4	1	7	1	1	2	9
Singapore	0	0	0	0	1	0	1	1
Taiwan	0	1	1	2	0	1	1	3
Total	7	12	11	30	17	28	45	75

Intent-to-treat (ITT) = patients who showed response to vedolizumab at 6 weeks and were randomized as part of the double-blind maintenance phase (maintenance ITT population); Non-ITT placebo = patients that were randomized to placebo during the induction phase and continued to received double-blind placebo during maintenance phase (maintenance safety population only); Non-ITT vedolizumab q4w = patients that did not show response to vedolizumab at 6 weeks and received open-label vedolizumab during the maintenance phase (maintenance safety population only); Placebo combined = all patients that received placebo during the maintenance phase; Vedolizumab combined = all patients that received vedolizumab during the maintenance phase.

q4w, every 4 weeks; q8w, every 8 weeks.